动物用药品市场－全球产业规模、份额、趋势、机会及预测（依产品类型、动物种类、感染疾病类型、最终用户、通路、地区及竞争格局划分，2021-2031年）

全球动物用药品市场预计将从2025年的280.1亿美元成长到2031年的397.6亿美元，复合年增长率（CAGR）为6.01%。该市场涵盖动物医药、疫苗和药用饲料添加剂的研发和销售，用于治疗和预防牲畜和通用动物的感染疾病。推动市场成长的关键因素包括全球对粮食安全日益增长的需求（这需要高效的畜牧管理）以及控制人畜共通病原体的迫切需求。此外，宠物饲主与其宠物之间日益深厚的情感纽带也显着推动了兽医支出。根据澳洲动物药品协会（Animal Medicines Australia）的报告，预计到2025年，该地区拥有宠物的家庭数量将达到3,160万户，其中73%的家庭拥有宠物，这凸显了支撑该行业的庞大消费群。

然而，日益严格的抗菌素抗药性监管为市场扩张带来了重大障碍。各国政府和国际卫生组织为保护公众健康，正在实施更严格的畜牧业抗生素使用规定，这为製药公司创造了必须遵守的严苛监管环境。这种环境限制了传统抗菌产品的市场竞争力，迫使生产者投入大量成本用于产品配方改良或开发替代疗法。因此，这些合规要求以及对非抗生素解决方案创新的需求，对全球市场的商业性发展构成了重大阻碍。

市场驱动因素

为满足全球日益增长的动物性蛋白质需求，畜牧业生产集约化程度不断提高，这是推动产业成长的主要因素。向高密度工业化生产模式的转变，虽然提高了生产效率，但也使牲畜更容易感染疾病，因此需要严格的管理通讯协定，包括疫苗接种、驱虫和使用含药饲料添加剂。依赖这些药物解决方案对于维护动物健康和满足国际食品安​​全标准至关重要。根据联合国粮食及农业组织（粮农组织）2024年6月发布的《粮食展望－世界粮食市场双年报告》，预计2024年全球肉类产量将达到3.71亿吨，这一规模凸显了药物保护对于防止疾病爆发造成经济损失的必要性。

同时，宠物人性化的趋势以及由此带来的医疗保健支出成长正在改变市场格局。饲主越来越将宠物视为家庭成员，并愿意为癌症和皮肤病等先进治疗支付更多费用，而不仅限于基础护理。宠物保险的日益普及进一步推动了这一转变，宠物保险可以涵盖高昂的兽医费用。根据北美宠物健康保险协会于2024年5月发布的《2024年产业趋势报告》，2023年美国宠物保险保费总额达39亿美元。在这些因素的共同推动下，该产业的蓬勃发展也体现在Zootis公司发布的2024年报告中，该公司宣布2023财年全年营收达85亿美元。

市场挑战

针对抗菌素抗药性的监管力道不断加大，已成为全球动物用药品市场成长的一大障碍。国际卫生组织和各国政府实施的严格法规直接限制了抗生素产品组合的商业性成功，而抗生素产品组合历来是动物医药公司稳定的收入来源。这种严苛的法规结构迫使生产商投入巨资重新配製现有产品，以消除促进生长的宣传并满足日益严格的监测要求，从而挤占了原本可用于拓展市场的资金。

这些法规的实际结果是全球抗菌药物销售量大幅下降，因为企业被迫减少对这类药物的依赖。 2024年，动物健康组织（Health for Animals）报告称，其成员公司2015年至2022年间的全球抗生素销售额下降了29.9%，显示该行业正经历结构性衰退。这种监管压力有效地限制了该治疗领域的成长前景，迫使整个产业进行高成本且复杂的转型，转向预防性医疗保健措施，而不是依赖现有产品线的持续商业性成功。

市场趋势

物种特异性单株抗体（mAb）的商业性应用正在从根本上改变治疗格局，为骨关节炎和皮肤病等慢性疾病提供标靶性强、毒性低的解决方案。与传统化学药物不同，这些生物製药透过精准的作用机制发挥作用，从而减少全身性副作用，这迫使生产商对专用基础设施进行大量投资，以满足日益增长的临床需求。这种向生物製药生产的结构性转变体现在重要的供应方倡议中。例如，礼来动物保健公司（Elanco Animal Health）在其2024年8月的新闻稿「礼来投资1.3亿美元扩大单株抗体生产」中宣布，将拨款1.3亿美元扩建其位于堪萨斯州的工厂，以增强其单株抗体的生产能力。这项投资凸显了该产业正稳步从广谱频谱转向先进的物种特异性治疗方法。

同时，兽医远距医疗与数位药局服务的整合正在改变动物用药品的处方、购买和配送方式。这一趋势将虚拟医疗平台与自动化电商物流相结合，形成一个无缝循环，不仅提高了用药依从性，也为数位领域的领导企业创造了持续的收入。这种自动化采购模式的优势在近期的财务表现中得到了充分体现。 Chewy公司在2024年3月发布的「2023财年致股东信」中报告称，其2023财年的自动续订销售额达到84.9亿美元，占总净销售额的76%以上。这一规模反映了消费者购买习惯的永久性结构性转变，即从一次性的诊所交易转向便利的订阅式数位医疗解决方案。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球动物用药品市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（药品、疫苗、药用饲料）
  • 依动物类型（伴侣动物、家畜）
  • 依给药途径（口服、注射、局部）
  • 依感染类型（病毒性、细菌性、寄生虫性、其他）分类
  • 依最终使用者（兽医院、动物诊所、照护现场/院内检测、其他）
  • 按分销管道（兽医诊所、药局/药局、电子商务）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美动物用药品市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲动物用药品市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太动物用药品市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲动物用药品市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美动物用药品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球动物用药品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Elanco Animal Health Incorporated
• CH Boehringer Sohn AG & Co. KG
• Merck & Co., Inc
• Ceva Sante Animale SA,
• Vetoquinol SA
• Bayer AG
• Virbac SA
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Animal Pharmaceuticals Market is projected to expand from USD 28.01 Billion in 2025 to USD 39.76 Billion by 2031, registering a CAGR of 6.01%. This market covers the research, development, and sale of veterinary medications, vaccines, and medicated feed additives designed to treat and prevent diseases in both livestock and companion animals. Growth is largely fueled by the rising global demand for food security, which necessitates efficient livestock management, and the increasing need to control zoonotic pathogens. Furthermore, the strengthening emotional connection between pet owners and their animals significantly boosts spending on veterinary care. As reported by Animal Medicines Australia, the pet population in that region reached an estimated 31.6 million in 2025, with 73% of households owning a pet, underscoring the vast consumer base supporting the industry.

Nevertheless, market expansion faces a major hurdle due to growing regulatory scrutiny concerning antimicrobial resistance. Governments and global health bodies are implementing stricter rules on antibiotic use in livestock to protect public health, creating a rigorous regulatory landscape that pharmaceutical companies must navigate. This environment limits the sales potential of traditional antimicrobial products and forces manufacturers to bear significant costs for reformulating products and developing alternative therapies. Consequently, these compliance demands and the need for innovation in non-antibiotic solutions create substantial barriers to the seamless commercial progression of the global market.

Market Driver

The push for intensified livestock production to satisfy the growing global appetite for animal protein serves as a primary catalyst for industry growth. As farming shifts toward high-density industrial models to optimize output, herds become more vulnerable to infectious diseases, requiring rigorous protocols involving vaccines, parasiticides, and medicated feed additives. This dependence on pharmaceutical solutions is essential for maintaining animal health and adhering to international food safety standards. According to the Food and Agriculture Organization's 'Food Outlook - Biannual Report on Global Food Markets' from June 2024, global meat production is predicted to reach 371 million tonnes in 2024, a scale that highlights the necessity of pharmaceutical protection to prevent economic losses caused by disease outbreaks.

Concurrently, the market is being transformed by the trend of pet humanization and the resulting increase in healthcare spending. Pet owners increasingly regard their animals as family members, leading to a greater willingness to pay for sophisticated treatments in areas like oncology and dermatology, moving beyond mere basic care. This transition is further bolstered by the rising utilization of pet insurance, which helps offset the costs of high-value veterinary procedures. As stated by the North American Pet Health Insurance Association in its 'State of the Industry Report 2024' released in May 2024, total pet insurance premiums in the U.S. hit $3.9 billion in 2023. The sector's financial vitality, driven by these combined factors, is reflected in Zoetis Inc.'s 2024 report, which announced a full-year revenue of $8.5 billion for the fiscal year 2023.

Market Challenge

Heightened regulatory attention regarding antimicrobial resistance poses a significant obstacle to the growth of the Global Animal Pharmaceuticals Market. International health authorities and governments are applying rigorous controls that directly constrain the commercial success of antibiotic portfolios, which have traditionally provided steady revenue for veterinary pharmaceutical firms. This strict regulatory framework compels manufacturers to invest heavily in reformulating existing products to eliminate growth-promotion claims and to meet enhanced surveillance mandates, diverting financial resources that could otherwise be used to fuel broader market expansion.

The practical consequence of these restrictions is a notable decrease in the global sales volume of antimicrobial agents, as companies are forced to decrease their dependence on these drug classes. According to HealthforAnimals, the association reported in 2024 that global antibiotic sales among its members fell by 29.9% between 2015 and 2022, signaling a structural decline in this segment. This regulatory pressure effectively limits the growth prospects of therapeutic drug categories, necessitating a costly and complicated industry shift toward preventative healthcare measures rather than relying on the continued commercial success of established product lines.

Market Trends

The widespread commercial adoption of species-specific monoclonal antibodies (mAbs) is radically changing the treatment landscape by offering targeted, low-toxicity solutions for chronic ailments like osteoarthritis and skin conditions. Unlike conventional chemical medications, these biologics function through precise mechanisms that reduce systemic side effects, driving manufacturers to invest significantly in specialized infrastructure to handle rising clinical needs. This structural move toward biological manufacturing is illustrated by major supply-side initiatives; for instance, Elanco Animal Health Incorporated announced in an August 2024 press release, 'Elanco Invests $130 Million in Expansion to Boost Monoclonal Antibody Production,' that it is allocating $130 million to expand its Kansas facility specifically to advance its monoclonal antibody capabilities. This investment underscores the industry's definitive shift from broad-spectrum drugs to advanced, species-specific biological therapies.

At the same time, the integration of veterinary telehealth with digital pharmacy services is transforming how animal health products are prescribed, bought, and supplied. This trend merges virtual care platforms with automated e-commerce fulfillment, establishing a seamless cycle that improves medication adherence and secures recurring revenue for digital leaders. The strength of these automated procurement models is clear in recent financial results; Chewy, Inc. noted in its 'Fiscal Year 2023 Letter to Shareholders' in March 2024 that Autoship sales hit $8.49 billion for fiscal year 2023, accounting for over 76% of total net sales. Such volume reflects a permanent structural shift in consumer purchasing habits, moving away from sporadic in-clinic transactions toward convenient, subscription-based digital health solutions.

Key Market Players

• Zoetis Inc.
• Elanco Animal Health Incorporated
• C.H. Boehringer Sohn AG & Co. KG
• Merck & Co., Inc
• Ceva Sante Animale S.A.,
• Vetoquinol S.A.
• Bayer AG
• Virbac SA
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals plc

Report Scope

In this report, the Global Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Pharmaceuticals Market, By Product Type

• Drugs
• Vaccine
• Medicated Feed

Animal Pharmaceuticals Market, By Animal Type

• Companion Animal
• Livestock Animal

Animal Pharmaceuticals Market, By Route of Administration

• Oral
• Parenteral
• Topical

Animal Pharmaceuticals Market, By Type of Infection

• Viral
• Bacterial
• Parasitic
• Others

Animal Pharmaceuticals Market, By End User

• Veterinary Hospitals
• Veterinary Clinics
• Point of care/In-house testing
• Others

Animal Pharmaceuticals Market, By Distribution Channel

• Veterinary Hospitals
• Pharmacies and Drug stores
• E-commerce

Animal Pharmaceuticals Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Pharmaceuticals Market.

Available Customizations:

Global Animal Pharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Pharmaceuticals Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Drugs, Vaccine, Medicated Feed)
  • 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
  • 5.2.4. By Type of Infection (Viral, Bacterial, Parasitic, Others)
  • 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Point of care/In-house testing, Others)
  • 5.2.6. By Distribution Channel (Veterinary Hospitals, Pharmacies and Drug stores, E-commerce)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Animal Pharmaceuticals Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Type of Infection
  • 6.2.5. By End User
  • 6.2.6. By Distribution Channel
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Pharmaceuticals Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Type of Infection
      • 6.3.1.2.5. By End User
      • 6.3.1.2.6. By Distribution Channel
  • 6.3.2. Canada Animal Pharmaceuticals Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Type of Infection
      • 6.3.2.2.5. By End User
      • 6.3.2.2.6. By Distribution Channel
  • 6.3.3. Mexico Animal Pharmaceuticals Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Type of Infection
      • 6.3.3.2.5. By End User
      • 6.3.3.2.6. By Distribution Channel

7. Europe Animal Pharmaceuticals Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Type of Infection
  • 7.2.5. By End User
  • 7.2.6. By Distribution Channel
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Pharmaceuticals Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Type of Infection
      • 7.3.1.2.5. By End User
      • 7.3.1.2.6. By Distribution Channel
  • 7.3.2. France Animal Pharmaceuticals Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Type of Infection
      • 7.3.2.2.5. By End User
      • 7.3.2.2.6. By Distribution Channel
  • 7.3.3. United Kingdom Animal Pharmaceuticals Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Type of Infection
      • 7.3.3.2.5. By End User
      • 7.3.3.2.6. By Distribution Channel
  • 7.3.4. Italy Animal Pharmaceuticals Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Type of Infection
      • 7.3.4.2.5. By End User
      • 7.3.4.2.6. By Distribution Channel
  • 7.3.5. Spain Animal Pharmaceuticals Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Type of Infection
      • 7.3.5.2.5. By End User
      • 7.3.5.2.6. By Distribution Channel

8. Asia Pacific Animal Pharmaceuticals Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Type of Infection
  • 8.2.5. By End User
  • 8.2.6. By Distribution Channel
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Pharmaceuticals Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Type of Infection
      • 8.3.1.2.5. By End User
      • 8.3.1.2.6. By Distribution Channel
  • 8.3.2. India Animal Pharmaceuticals Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Type of Infection
      • 8.3.2.2.5. By End User
      • 8.3.2.2.6. By Distribution Channel
  • 8.3.3. Japan Animal Pharmaceuticals Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Type of Infection
      • 8.3.3.2.5. By End User
      • 8.3.3.2.6. By Distribution Channel
  • 8.3.4. South Korea Animal Pharmaceuticals Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Type of Infection
      • 8.3.4.2.5. By End User
      • 8.3.4.2.6. By Distribution Channel
  • 8.3.5. Australia Animal Pharmaceuticals Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Type of Infection
      • 8.3.5.2.5. By End User
      • 8.3.5.2.6. By Distribution Channel

9. Middle East & Africa Animal Pharmaceuticals Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Type of Infection
  • 9.2.5. By End User
  • 9.2.6. By Distribution Channel
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Pharmaceuticals Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Type of Infection
      • 9.3.1.2.5. By End User
      • 9.3.1.2.6. By Distribution Channel
  • 9.3.2. UAE Animal Pharmaceuticals Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Type of Infection
      • 9.3.2.2.5. By End User
      • 9.3.2.2.6. By Distribution Channel
  • 9.3.3. South Africa Animal Pharmaceuticals Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Type of Infection
      • 9.3.3.2.5. By End User
      • 9.3.3.2.6. By Distribution Channel

10. South America Animal Pharmaceuticals Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Type of Infection
  • 10.2.5. By End User
  • 10.2.6. By Distribution Channel
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Pharmaceuticals Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Type of Infection
      • 10.3.1.2.5. By End User
      • 10.3.1.2.6. By Distribution Channel
  • 10.3.2. Colombia Animal Pharmaceuticals Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Type of Infection
      • 10.3.2.2.5. By End User
      • 10.3.2.2.6. By Distribution Channel
  • 10.3.3. Argentina Animal Pharmaceuticals Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Type of Infection
      • 10.3.3.2.5. By End User
      • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Pharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Elanco Animal Health Incorporated
• 15.3. C.H. Boehringer Sohn AG & Co. KG
• 15.4. Merck & Co., Inc
• 15.5. Ceva Sante Animale S.A.,
• 15.6. Vetoquinol S.A.
• 15.7. Bayer AG
• 15.8. Virbac SA
• 15.9. Phibro Animal Health Corporation
• 15.10. Dechra Pharmaceuticals plc

16. Strategic Recommendations

17. About Us & Disclaimer